A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 70
Summary
- Conditions
- Lymphoma Non-Hodgkin
- Neoplasms
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02875223
- Collaborators
- Not Provided
- Investigators
- Study Director: Zariana Nikolova, MD, PhD Celgene Corporation Principal Investigator: Johann De Bono, MD, PhD Royal Marsden NHS Foundation Trust Principal Investigator: Antoine Hollebecque, MD Gustave Roussy, Cancer Campus, Grand Paris